Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the… Read more
Longboard Pharmaceuticals Inc (LBPH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.075x
Based on the latest financial reports, Longboard Pharmaceuticals Inc (LBPH) has a cash flow conversion efficiency ratio of -0.075x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.59 Million) by net assets ($275.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Longboard Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Longboard Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Longboard Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Longboard Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
X Trade Brokers Dom Maklerski SA
WAR:XTB
|
0.044x |
|
O-I Glass Inc
NYSE:OI
|
0.174x |
|
Region Group
AU:RGN
|
0.031x |
|
Antong Holdings Co Ltd
SHG:600179
|
0.030x |
|
Gland Pharma Limited
NSE:GLAND
|
0.062x |
|
Sharp Corporation
PINK:SHCAF
|
0.014x |
|
Universal Technical Institute Inc
NYSE:UTI
|
0.174x |
|
Intea Fastigheter B
ST:INTEA-B
|
N/A |
Annual Cash Flow Conversion Efficiency for Longboard Pharmaceuticals Inc (2020–2023)
The table below shows the annual cash flow conversion efficiency of Longboard Pharmaceuticals Inc from 2020 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $40.92 Million | $-50.87 Million | -1.243x | -100.74% |
| 2022-12-31 | $61.47 Million | $-38.06 Million | -0.619x | -158.97% |
| 2021-12-31 | $103.32 Million | $-24.70 Million | -0.239x | -268.89% |
| 2020-12-31 | $53.10 Million | $-3.44 Million | -0.065x | -- |